This is a Glucagon news story, published by Live Science, that relates primarily to GLP-RAs news.
For more Glucagon news, you can click here:
more Glucagon newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Live Science, you can click here:
more news from Live ScienceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
insulin. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest receptor agonists news, diabetes news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
loss drugsLive Science
•Health
Health
81% Informative
Glucagon -like peptide peptide 1 receptor agonists ( GLP-1RAs ) have become increasingly popular over the past decade for the treatment of type 2 diabetes and obesity.
In a new study, scientists compiled what they say is the clearest ever picture of the effectiveness and risks associated with taking GLP-RAs .
The study assessed the health of 215,000 people with diabetes over four years .
VR Score
90
Informative language
93
Neutral language
82
Article tone
semi-formal
Language
English
Language complexity
60
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
11
Source diversity
11
Affiliate links
2
